Meihua International Medical Technologies (NASDAQ:MHUA) is a China-based developer and manufacturer of interventional medical devices with a focus on cardiovascular and ophthalmic applications. Since its inception, the company has invested heavily in research and development to deliver a range of products designed to meet the needs of hospitals, clinics and healthcare professionals. Meihua’s portfolio spans from drug-eluting stents and balloon catheters to intraocular lenses, reflecting its commitment to advancing minimally invasive treatment options.
Within its cardiovascular segment, Meihua produces a broad array of devices, including bioresorbable and metal drug-coated stents, plain balloon catheters and guide wires. These products are used in the treatment of coronary artery disease, peripheral vascular disease and related disorders. The company operates multiple manufacturing facilities in China, each holding relevant certifications for quality management and medical device production, and maintains an in-house team of engineers and scientists dedicated to product innovation and regulatory compliance.
In the ophthalmic arena, Meihua offers hydrophobic acrylic and silicone intraocular lenses for cataract surgery, as well as foldable lens injectors and related surgical consumables. Its ophthalmic products are developed to deliver enhanced visual outcomes while ensuring biocompatibility and ease of implantation. The company collaborates with leading eye hospitals and academic institutions to refine lens designs and expand indications, aiming to capture a growing market driven by aging demographics and rising demand for vision correction procedures.
Headquartered in Beijing, Meihua International Medical Technologies serves customers across China and exports to regions including Southeast Asia, Latin America and select European markets. The company’s leadership team combines seasoned executives from the medical device industry with academic experts in biomedical engineering. Under the direction of Chairman Xiaodong Chen and CEO Liwei Zhao, Meihua continues to pursue geographic expansion, regulatory approvals in new jurisdictions and strategic partnerships to bolster its product pipeline and global footprint.
AI Generated. May Contain Errors.
